NeuroGyn Genital Neuromodulation System for iOAB Treatment

NCT06529198 | Not Yet Recruiting

• 1 other identifier: NeuroGyn AG
• Study Type: interventional
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

The NeuroGyn study is designed to evaluate the safety and effectiveness to the NeuroGyn Genital Neuromodulation System as an aid in the treatment of the symptoms of idiopathic overactive bladder in patients who have failed or could not tolerate more conservative treatments.

Conditions

Overactive Bladder

Outcome Measures

Primary Outcomes (2)

• Reduction in Symptoms greater than or equal to 50%

  Overactive Bladder Symptom Score - OABSS

  6 months - 1 year - 2 years follow up

• Urodynamic testing

  Noninvasive uroflowmetry, followed by invasive cystometry and a pressure-flow study + concurrent electromyography (EMG) of pelvic floor muscles and urethral pressure profiles

  6 months - 1 year - 2 years

Secondary Outcomes (2)

• International Consultation on Incontinence Questionnaire

  6 months - 1 year - 2 years

• The PHQ-9 (Patient Health Questionnaire-9)

  6 months - 1 year - 2 years

Study Arms (1)

treatment

EXPERIMENTAL

Patient are undergoing neuromodulatioon

Device: NeuroGyn Genital Neuromodulation System

Interventions

NeuroGyn Genital Neuromodulation System DEVICE

Genital Neuromodulation

treatment

Eligibility Criteria

• Age: 18 Years - 85 Years
• Gender Eligibility Details: femal and male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age and older (adult and older adult, all sexes)
• Diagnosed (urodynamic testing) with idiopathic overactive bladder (iOAB)
• Symptoms of urinary urgency, frequency, and/or urge incontinence for at least 6 months
• Failed conservative treatments (e.g., lifestyle modifications, medications)
• Willing and capable of providing informed consent
• Capable of participating in all testing associated with this clinical investigation
• Patients have already undergo a successful GNS-test phase with adhesive electrodes (reduction symptoms greater equal or more than 50%)

You may not qualify if:

• History of pelvic surgery affecting the pubic bone or genital nerves
• Current urinary tract infection
• Neurological conditions affecting bladder function (neurogenic OAB)
• Pregnancy or planning to become pregnant during the study period
• Contraindications to local anesthesia or surgery
• Female patients with significant prolapse (i.e., prolapse beyond the introitus).
• Patients with primary stress incontinence and primary pelvic pain symptoms.
• Patients with less than 12 months from last intravesical botulinum toxin A therapy
• Patients with mechanical infravesical obstruction and/or Interstitial Cystitis.
• Vulnerable patients with co-morbid conditions should be excluded from this study. These co-morbid conditions include all pathologies of the cardiovascular system (Angina Pectoris, Infarct, Thrombose, Embolie, Hypertonia), pulmonary system (asthma, COPD, chr. Bronchitis), intestinal system (morbus Crohn, diverticulitis..) and any malignant disease. These co-morbid conditions also include neurologic diseases (i.e., stroke, multiple sclerosis, spinal cord injury), sacral dermal pathological conditions, congenital or other anatomical sacral anomalies (e.g. spina bifida, sacral agenesis, trauma sequelae), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTIs), gross hematuria, prior pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate), deeply infiltrating endometriosis of the pelvic plexus, sacral plexus or of the bladder, Reiter´s syndrome, and pelvic radiation.
• Patients suffering from other CNS disorders (mental disorders, severe psychological problems, cerebrovascular accident less than 6 months ago).
• Patients suffering from polydipsia/polyuria are excluded from the study. Similarly, patients suffering from diabetes insipidus (DI) and diabetes mellitus (DM) are also excluded from the study.
• A female with a positive urine pregnancy test
• A female who is breastfeeding
• Allergies again local anesthesia (Lidocain), Tranquillizers and Antibiotics

Sponsors & Collaborators

• Prof. Dr. med. Marc Possover: lead

MeSH Terms

Conditions

Urinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Marc Possover, PhD

CONTACT

+41797507595; m.possover@possover.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PhD MD

Model Details: Single Group Assignment

Study Record Dates

• First Submitted: July 13, 2024
• First Posted: July 31, 2024
• Study Start: August 1, 2025
• Primary Completion: February 1, 2026
• Study Completion: April 1, 2026
• Last Updated: July 31, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share